Insulin-like growth factor binding proteins modulate Müller cell responses to insulin-like growth factors

Investigative Ophthalmology and Visual Science

Volumn 45, Issue 8, 2004, Pages 2848-2855

  King, Jeffery L ^a   Guidry, Clyde ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN GEL; PROTEINASE; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN;

ANIMAL TISSUE; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; DIABETES MELLITUS; MUELLER CELL; NONHUMAN; PRIORITY JOURNAL; VITREOUS BODY; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; LIGANDS; NEUROGLIA; SWINE;

EID: 3242880370     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.04-0054     Document Type: Article

References (48)

1. Aiello LP, TW Gardner, GL King, et al. Diabetic retinopathy. Diabetes Care. 1998;21:143-156.
2. Davis M. Diabetic retinopathy: a clinical overview. Diabetes Care. 1992;15:1844-1874.
3. Neely K, Quillen D, Schahat A, Gardner T, Blankenship G. Diabetic retinopathy. Med Clin North Am. 1998;82:847-876.
4. Bringmann A, Reichenbach A. Role of Müller cells in retinal degenerations. Front Biosci. 2001;6:E72-E92.
5. Amin RH, Frank RN, Kennedy A, Eliott D, Puklin JE, Abrams GW. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. Invest Ophthalmol Vis Sci. 1997;38:36-47.
6. Holopigian K, Seiple W, Lorenzo M, Carr R. A comparison of photopic and scotopic electroretinographic changes in early diabetic retinopathy. Invest Ophthalmol Vis Sci. 1992;33:2773-2780.
7. Leith W, Barber AJ, Xu B, et al. Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy. Diabetes. 1998;47:815-820.
8. Mizutani M, Gerhardinger C, Lorenzi M. Müller cell changes in human diabetic retinopathy. Diabetes. 1998;47:445-449.
9. Tzekov R Arder GB. The electroretinogram in diabetic retinopathy. Surv Ophthalmol. 1999;44:53-60.
10. Nork TM, Wallow IHL, Sramek SJ, Anderson G. Müller's cell involvement in proliferative diabetic retinopathy. Arch Ophthalmol. 1987;105:1424-1429.
11. Sramek SJ, Wallow IH, Stevens TS, Nork TM. Immunostaining of preretinal membranes for actin, fibronectin, and glial fibrillary acidic protein. Ophthalmology. 1989;96:835-841.
12. Guidry C. Tractional force generation by porcine Müller cells: development and differential stimulation by growth factors. Invest Ophthalmol Vis Sci. 1997;38:456-468.
13. Peters MA, Burke JM, Clowry M, Abrams GW, Williams GA. Development of traction retinal detachments following intravitreal injections of retinal Müller and pigment epithelial cells. Graefes Arch Clin Exp Ophthalmol. 1986;224:554-563.
14. Ikeda T, Puro DG. Regulation of retinal glial cell proliferation by antiproliferative molecules. Exp Eye Res. 1995;60:435-443.
15. Ikeda T, Waldbillig RJ, Puro DG. Truncation of IGF-I yields two mitogens for retinal Müller glial cells. Brain Res. 1995;686:87-92.
16. Uchihori Y, Puro DG. Mitogenic and chemotactic effects of platelet-derived growth factor on human retinal glial cells. Invest Ophthalmol Vis Sci. 1991;32:2689-2695.
17. Guidry C, Bradley KM, King JL. Tractional force generation by human Müller cells: growth factor responsiveness and integrin receptor involvement. Invest Ophthalmol Vis Sci. 2003;44:1355-1363.
18. Freyberger H, Brocker M, Yakut H, et al. Increased levels of platelet-derived growth factor in vitreous fluid of patients with proliferative diabetic retinopathy. Exp Clin Endocrinol Diabetes. 2000;108:106-109.
19. Boulton M, Gregor Z, McLeod D, et al. Intravitreal growth factors in proliferative diabetic retinopathy: correlation with neovascular activity and glycaemic management. Br J Ophthalmol. 1997;81:228-233.
20. Burgos R, Mateo C, Canton A, Hernandez C, Mesa J, Simo R. Vitreous levels of IGF-I, IGF binding protein 1, and IGF binding protein 3 in proliferative diabetic retinopathy: a case-control study. Diabetes Care. 2000;23:80-83.
21. Grant M, Russel B, Fitzgerald C, Merimee T. Insulin-like growth factors in vitreous: studies in control and diabetic subjects with neovascularization. Diabetes. 1986;35:416-420.
22. Inokuchi N, Ikeda T, Imamura Y, et al. Vitreous levels of insulin-like growth factor-I in patients with proliferative diabetic retinopathy. Curr Eye Res. 2001;23:368-371.
23. Meyer-Schwickerath R, Pfeiffer A, Blum WF, et al. Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects. J Clin Invest. 1993;92:2620-2625.
24. Spranger J, Buhnen J, Jansen V. et al. Systemic levels contribute significantly to increased intraocular IGF-I, IGF-II and IGF-BP3 [correction of IFG-BP3] in proliferative diabetic retinopathy. Horm Metab Res. 2000;32:196-200.
25. Spranger J, Mohlig M, Osterhoff M, Buhnen J, Blum WF, Pfeiffer AF. Retinal photocoagulation does not influence intraocular levels of IGF-I, IGF-II and IGF-BP3 in proliferative diabetic retinopathy-evidence for combined treatment of PDR with somatostatin analogues and retinal photocoagulation? Horm Metab Res. 2001;33:312-316.
26. Hardwick C, Feist R, Morris R, et al. Tractional force generation by porcine Müller cells: stimulation by growth factors in human vitreous. Invest Ophthalmol Vis Sci. 1997;38:2053-2063.
27. Guidry C, Feist R, Morris R, Hardwick CW. Changes in insulin-like growth factor activities in human diabetic vitreous. Diabetes. In press.
28. Arnold DR, Moshayedi P, Schoen TJ, Jones BE, Chader GJ, Waldbillig RJ. Distribution of IGF-I and -II, IGF binding proteins (IGFBPs) and IGFBP mRNA in ocular fluids and tissues: potential sites of synthesis of IGFBPs in aqueous and vitreous. Exp Eye Res. 1993;56:555-565.
29. Collett-Soberg PR, Cohen P. The role of the insulin-like growth factor binding proteins and the IGFBP proteases inmodulating IGF action. Endo Met Dis Clin North Am. 1996;25:591-614.
30. LeRoith D. Insulin-like growth factors. N Engl J Med. 1997;336:633-640.
31. Schoen TJ, Beebe DC, Clemmons DR, Chader GJ, Waldbillig RJ. Local synthesis and developmental regulation of avian vitreal insulin-like growth factor-binding proteins: a model for independent regulation in extravascular and vascular compartments. Endocrinology. 1992;131:2846-2854.
32. Waldbillig RJ, Jones BE, Schoen TJ, et al. Vitreal insulin-like growth factor binding proteins (IGFBPs) are increased in human and animal diabetics. Curr Eye Res. 1994;13:539-546.
33. Hopkins KD, Brart DO, Russell Jones DL, Chignell AH, Sonksen PH. Insulin-like growth factor binding protein-1 levels in diabetic proliferative retinopathy. Horm Metab Res. 1993;25:331-332.
34. Yang YW, Brown DR, Robcis HL, Rechler MM, de Pablo F. Developmental regulation of insulin-like growth factor binding protein-2 in chick embryo serum and vitreous humor. Regulatory Peptides. 1993;48:145-155.
35. de la Rosa EJ, Bondy CA, Hernandez-Sanchez C, et al. Insulin and insulin-like growth factor system components gene expression in the chicken retina from early neurogenesis until late development and their effect on neuroepithelial cells. Eur J Neurosci. 1994;6:1801-1810.
36. Frystyk J, Bek T, Flyvbjerg A, Skjaerback C, Orskov H. The relationship between the circulating IGF system and the presence of retinopathy in type 1 diabetic patients. Diabet Med. 2003;20:269-276.
37. Pfeiffer A, Spranger J, Meyer-Schwickerath R, Schatz H. Growth factor alterations in advanced diabetic retinopathy: a possible role of blood retina barrier breakdown. Diabetes. 1997;46(suppl 2): S26-S30.
38. Moshyedi P, Schoen TJ, Searcy GD, et al. Vitreous and aqueous humors contain a latent proteinase activity that abolishes IGF binding to specific IGF binding proteins. Curr Eye Res. 1995;14:555-561.
39. Schoen TJ, Waldbillig RJ, Searcy G, et al. Identification and partial characterization of a proteinase specific for insulin-like growth factor binding protein-3 in aqueous and vitreous humors. Curr Eye Res. 1995;14:127-135.
40. Conover CA. Regulation and physiological role of insulin-like growth factor binding proteins. Endocr J. 1996;43:S43-S48.
41. Baxter RC. Molecular aspects of insulin-like growth factor binding proteins. In: LeRoith, D, ed. Advances in Molecular and Cellular Endocrinology. Greenwich, CT: JAI Press; 1997;123-159.
42. Laemmli U. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;74:856-875.
43. Rajaram S, Baylink DJ, Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev. 1997;18:801-831.
44. Coverley JA, Baxter RC. Phosphorylation of insulin-like growth factor binding proteins. Mol Cell Endocrinol. 1997;128:1-5.
45. Mohseni-Zadeh S, Binoux M. Insulin-like growth factor (IGF) binding protein-3 interacts with the type 1 IGF receptor, reducing the affinity of the receptor for its ligand: an alternative mechanism in the regulation of IGF action. Endocrinology. 1997;138:5645-5648.
46. Imbenotte J, Liu L, Desauty G, Harel L. Stimulation by TGF beta of chick embryo fibroblasts: inhibition by an IGFBP-3. Exp Cell Res., 1992;199:229-233.
47. Villaudy J, Delbe J, Blat C, Desauty G, Golde A, Harel L. An IGF binding protein is an inhibitor of FGF stimulation. J Cell Physiol. 1991;149:492-496.
48. Simo R, Hernandez C, Segura RM, et al. Free insulin-like growth factor 1 in the vitreous fluid of diabetic patients with proliferative diabetic retinopathy: a case-control study. Clin Sci (Lond), 2003;104:223-230.